3VG Stock Overview
Theranexus Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Theranexus Société Anonyme Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.06 |
| 52 Week High | €2.02 |
| 52 Week Low | €0.58 |
| Beta | 2.34 |
| 1 Month Change | 1.44% |
| 3 Month Change | 39.55% |
| 1 Year Change | -32.20% |
| 3 Year Change | -91.86% |
| 5 Year Change | n/a |
| Change since IPO | -93.05% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3VG | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0.5% | 2.6% | 1.9% |
| 1Y | -32.2% | -22.6% | 5.9% |
Return vs Industry: 3VG underperformed the German Pharmaceuticals industry which returned -22.6% over the past year.
Return vs Market: 3VG underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 3VG volatility | |
|---|---|
| 3VG Average Weekly Movement | 16.8% |
| Pharmaceuticals Industry Average Movement | 7.1% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 3VG's share price has been volatile over the past 3 months.
Volatility Over Time: 3VG's weekly volatility has increased from 11% to 17% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 19 | Mathieu Charvériat | www.theranexus.com |
Theranexus Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for Batten disease. The company was founded in 2013 and is headquartered in Lyon, France.
Theranexus Société Anonyme Fundamentals Summary
| 3VG fundamental statistics | |
|---|---|
| Market cap | €8.81m |
| Earnings (TTM) | -€6.83m |
| Revenue (TTM) | €319.00k |
27.6x
P/S Ratio-1.3x
P/E RatioIs 3VG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3VG income statement (TTM) | |
|---|---|
| Revenue | €319.00k |
| Cost of Revenue | €5.08m |
| Gross Profit | -€4.76m |
| Other Expenses | €2.07m |
| Earnings | -€6.83m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 26, 2024
| Earnings per share (EPS) | -0.88 |
| Gross Margin | -1,491.22% |
| Net Profit Margin | -2,140.44% |
| Debt/Equity Ratio | 147.3% |
How did 3VG perform over the long term?
See historical performance and comparison